(RTTNews) - Natera, Inc. (NTRA), a diagnostics company, Monday announced that it has acquired the non-invasive pre-natal screening and carrier screening business of medical genetics company, Invitae (NVTA).
Natera has made an upfront payment of $10 million and will pay an additional $42.5 million as potential milestone payments to Invitae.
On the other hand, Invitae will transition its non-invasive prenatal screening and carrier screening to Natera's customers.
On Friday, Natera shares closed at $66.63, down 1.38% on the Nasdaq and in pre-market activity, Invitae shares are trading at $0.44, up 3.51% on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
